$28.61
1.49% day before yesterday
Nasdaq, Nov 21, 10:00 pm CET
ISIN
IE00B56GVS15
Symbol
ALKS

Alkermes Plc Stock price

$28.61
-2.84 9.03% 1M
-1.92 6.29% 6M
-0.15 0.52% YTD
+0.91 3.29% 1Y
+5.25 22.48% 3Y
+10.67 59.50% 5Y
-42.76 59.91% 10Y
+9.98 53.60% 20Y
Nasdaq, Closing price Fri, Nov 21 2025
+0.42 1.49%

Key metrics

Basic
Market capitalization
$4.7b
Enterprise Value
$3.6b
Net debt
positive
Cash
$1.1b
Shares outstanding
165.1m
Valuation (TTM | estimate)
P/E
14.2 | 19.0
P/S
3.1 | 3.2
EV/Sales
2.4 | 2.4
EV/FCF
7.4
P/B
2.7
Financial Health
Equity Ratio
71.3%
Return on Equity
25.1%
ROCE
19.3%
ROIC
26.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.5b | $1.5b
EBITDA
$364.7m | $358.1m
EBIT
$358.9m | $224.7m
Net Income
$339.3m | $248.9m
Free Cash Flow
$491.3m
Growth (TTM | estimate)
Revenue
1.1% | -4.0%
EBITDA
-19.4% | -16.2%
EBIT
-17.8% | -46.6%
Net Income
2.0% | -32.2%
Free Cash Flow
55.9%
Margin (TTM | estimate)
Gross
86.0%
EBITDA
24.0% | 23.9%
EBIT
23.6%
Net
22.3% | 16.6%
Free Cash Flow
32.3%
More
EPS
$2.0
FCF per Share
$3.0
Short interest
14.0%
Employees
2k
Rev per Employee
$870.0k
Show more

Is Alkermes Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Alkermes Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Alkermes Plc forecast:

18x Buy
82%
4x Hold
18%

Analyst Opinions

22 Analysts have issued a Alkermes Plc forecast:

Buy
82%
Hold
18%

Financial data from Alkermes Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,521 1,521
1% 1%
100%
- Direct Costs 212 212
16% 16%
14%
1,309 1,309
5% 5%
86%
- Selling and Administrative Expenses 661 661
4% 4%
43%
- Research and Development Expense 283 283
77% 77%
19%
365 365
19% 19%
24%
- Depreciation and Amortization 5.81 5.81
64% 64%
0%
EBIT (Operating Income) EBIT 359 359
18% 18%
24%
Net Profit 339 339
2% 2%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Alkermes Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alkermes Plc Stock News

Positive
Reuters
4 days ago
Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.
Neutral
PRNewsWire
4 days ago
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached agreement ...
Neutral
Seeking Alpha
6 days ago
Alkermes plc ( ALKS ) Shareholder/Analyst Call November 12, 2025 8:30 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Craig Hopkinson - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Joon Lee - Truist Securities, Inc., Research Division Julian Pino - Stifel...
More Alkermes Plc News

Company Profile

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Richard Pops
Employees 1,800
Founded 2011
Website www.alkermes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today